Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Organigram Global's enterprise value is €120.1 Mil.
Organigram Global's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €3.5 Mil. Therefore, Organigram Global's EV-to-EBITDA for today is 34.77.
The historical rank and industry rank for Organigram Global's EV-to-EBITDA or its related term are showing as below:
STU:0OG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6798.29 Med: -1.12 Max: 168.28
Current: 34.53
During the past 13 years, the highest EV-to-EBITDA of Organigram Global was 168.28. The lowest was -6798.29. And the median was -1.12.
STU:0OG's EV-to-EBITDA is ranked worse than 82.41% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.37
vs STU:0OG: 34.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Organigram Global (STU:0OG) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Organigram Global's PE Ratio (TTM) for today is calculated as:
Organigram Global's share price for today is €0.84.
Organigram Global's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.128.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Organigram Global's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organigram Global EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organigram Global's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Organigram Global's EV-to-EBITDA falls into.
Organigram Global's current Enterprise Value is €120.1 Mil.
Organigram Global's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organigram Global (STU:0OG) has a EV-to-EBITDA of 34.77 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Organigram Global. According to the industry distribution chart, Organigram Global ranks #609 out of 739 companies in the Drug Manufacturers industry, placing it in the top 82.4%.
Is Organigram Global's EV-to-EBITDA too high?
Organigram Global's current EV-to-EBITDA is 34.77. The Drug Manufacturers industry median EV-to-EBITDA is 13.37. Organigram Global's value of 34.77 is 160.1% above this industry median. Based on the distribution chart, Organigram Global ranks #609 out of 739 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Organigram Global has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Organigram Global ranks #609 out of 739 companies for EV-to-EBITDA. This places Organigram Global in the lower half of its industry. The industry median EV-to-EBITDA is 13.37. Organigram Global's value of 34.77 is 160.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.37, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organigram Global's current EV-to-EBITDA of 34.77 is 160.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Organigram Global. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organigram Global's current EV-to-EBITDA is 34.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.59, compared to a current price of €0.84 — trading 47.2% below its estimated fair value. The current EV-to-EBITDA is 34.77 and 160.1% above the Drug Manufacturers industry median of 13.37. Organigram Global's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current EV-to-EBITDA is 34.77 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organigram Global (STU:0OG) Overvalued in 2026?
Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued.
The current stock price of €0.84 is trading 47.2% below its estimated GF Value™ of €1.59.
GuruFocus considers Organigram Global to be Possible Value Trap.
Key valuation signals for STU:0OG:
EV-to-EBITDA: 34.77
GF Value™: €1.59 vs. price of €0.84 (47.2% below fair value)
Industry Position: 160.1% above the Drug Manufacturers median (#609 of 739)
No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
60GF Score
Get the complete analysis for STU:0OG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0OG has been successfully added to your 
